标题
Half-life extension technologies for haemostatic agents
作者
关键词
-
出版物
THROMBOSIS AND HAEMOSTASIS
Volume 113, Issue 1, Pages 165-176
出版商
Schattauer GmbH
发表日期
2014-10-02
DOI
10.1160/th14-04-0332
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII
- (2014) Sabine Zollner et al. THROMBOSIS RESEARCH
- Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats
- (2014) Eva Herzog et al. THROMBOSIS RESEARCH
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2013) David Moher ANNALS OF INTERNAL MEDICINE
- A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
- (2013) H. R. Stennicke et al. BLOOD
- Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
- (2013) J. Mahlangu et al. BLOOD
- Diagnosis and Treatment of Invasive Fungal Infections Focus on Liposomal Amphotericin B
- (2013) João F. Lacerda et al. CLINICAL DRUG INVESTIGATION
- Optimizing asparaginase therapy for acute lymphoblastic leukemia
- (2013) Carmelo Rizzari et al. CURRENT OPINION IN ONCOLOGY
- Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis C
- (2013) Nicolas Flori et al. DRUGS
- 40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors
- (2013) R. Ljung et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Recommendations on the potency labelling of factor VIII and factor IX concentrates
- (2013) A. R. Hubbard et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A
- (2013) A. Tiede et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers
- (2013) G. Golor et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
- (2013) S. Zollner et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
- (2013) Jerry S. Powell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin
- (2013) Steven W. Pipe et al. THROMBOSIS AND HAEMOSTASIS
- PROLONG-9FP clinical development program – phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP)
- (2013) Elena Santagostino THROMBOSIS RESEARCH
- Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII
- (2013) Stefan Schulte THROMBOSIS RESEARCH
- Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII
- (2013) Sabine B. Zollner et al. THROMBOSIS RESEARCH
- Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B
- (2013) Uri Martinowitz et al. THROMBOSIS RESEARCH
- High Molecular Weight Polyethylene Glycol Cellular Distribution and PEG-associated Cytoplasmic Vacuolation Is Molecular Weight Dependent and Does Not Require Conjugation to Proteins
- (2013) Daniel G. Rudmann et al. TOXICOLOGIC PATHOLOGY
- The hope and reality of long-acting hemophilia products
- (2012) Steven W. Pipe AMERICAN JOURNAL OF HEMATOLOGY
- Safety of Modern Starches Used During Surgery
- (2012) Philippe Van Der Linden et al. ANESTHESIA AND ANALGESIA
- How we choose factor VIII to treat hemophilia
- (2012) P. M. Mannucci et al. BLOOD
- Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs
- (2012) J. A. Dumont et al. BLOOD
- Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
- (2012) J. S. Powell et al. BLOOD
- Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients
- (2012) E. Santagostino et al. BLOOD
- Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents
- (2012) Ricardo P Garay et al. Expert Opinion on Drug Delivery
- PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers
- (2012) I. A. Ivens et al. HAEMOPHILIA
- Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs
- (2012) H. Agersø et al. HAEMOPHILIA
- Doxil® — The first FDA-approved nano-drug: Lessons learned
- (2012) Yechezkel (Chezy) Barenholz JOURNAL OF CONTROLLED RELEASE
- Conformational Comparability of Factor IX–Fc Fusion Protein, Factor IX, and Purified Fc Fragment in the Absence and Presence of Calcium
- (2012) Damian Houde et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs
- (2012) M. W. NOLTE et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Hyperglycosylation prolongs the circulation of coagulation factor IX
- (2012) G. BOLT et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX
- (2012) P. W. COLLINS et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein
- (2012) R. T. PETERS et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients
- (2012) J. Powell et al. THROMBOSIS AND HAEMOSTASIS
- Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor
- (2012) Jan Terje Andersen et al. Nature Communications
- PEGylation of a Factor VIII–Phosphatidylinositol Complex: Pharmacokinetics and Immunogenicity in Hemophilia A Mice
- (2011) Aaron Peng et al. AAPS Journal
- Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide
- (2011) H. Ostergaard et al. BLOOD
- Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients
- (2011) A. D. Shapiro et al. BLOOD
- Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B
- (2011) C. Negrier et al. BLOOD
- Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008
- (2011) S. GUH et al. HAEMOPHILIA
- Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008
- (2011) S. GUH et al. HAEMOPHILIA
- GlycoPEGylated rFVIIa (N7-GP) has a prolonged hemostatic effect in hemophilic mice compared with rFVIIa
- (2011) H. HOLMBERG et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)
- (2011) A. GRINGERI et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects
- (2011) J. MØSS et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa
- (2011) Ditte M. Karpf et al. THROMBOSIS RESEARCH
- Prolonged activity of factor IX as a monomeric Fc fusion protein
- (2010) R. T. Peters et al. BLOOD
- Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
- (2010) B. Mei et al. BLOOD
- N-Glycosylation Increases the Circulatory Half-Life of Human Growth Hormone
- (2010) Thomas V. Flintegaard et al. ENDOCRINOLOGY
- Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII - an open label, exploratory, cross-over, phase I/II study
- (2010) J. SPIRA et al. HAEMOPHILIA
- Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma
- (2010) Søren E. Bjørn et al. THROMBOSIS AND HAEMOSTASIS
- Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice
- (2009) J. Pan et al. BLOOD
- Prophylactic therapy in haemophilia
- (2009) Rolf Ljung BLOOD REVIEWS
- Emerging PEGylated drugs
- (2009) Jung Seok Kang et al. EXPERT OPINION ON EMERGING DRUGS
- Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes
- (2009) I. DAYAN et al. HAEMOPHILIA
- Effect of glycoPEGylation on factor VIIa binding and internalization
- (2009) P. SEN et al. HAEMOPHILIA
- Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens
- (2009) P. W. COLLINS et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A
- (2008) U. MARTINOWITZ et al. HAEMOPHILIA
- Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes
- (2008) R. YATUV et al. HAEMOPHILIA
- Passive Transfer of Polyethylene Glycol to Liposomal-Recombinant Human FVIII Enhances its Efficacy in a Murine Model for Hemophilia A
- (2008) Karthik Ramani et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A
- (2008) J. S. POWELL et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa
- (2008) Stefan Schulte THROMBOSIS RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now